Skip to main content
KARD
NASDAQ Life Sciences

Kardigan Completes KATALYST-AV Enrollment; Pushes AVC Endpoint to Week 48, Topline Now 2H 2027

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Neutral
Importance info
7
Price
$15.93
Mkt Cap
$1.451B
52W Low
$12.23
52W High
$27
52W Position info
30% above low
Off High info
41% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

KARD sits 30% above its 52-week low of $12.23.

Summary

Kardigan finished enrolling 156 patients in the Phase 2b KATALYST-AV trial of ataciguat in aortic stenosis, but amended the protocol so the primary valve-calcium endpoint is assessed at Week 48, pushing topline data to the second half of 2027.


Key Events · Product Development and Regulatory · KARD

  • KATALYST-AV Enrollment Complete

    Kardigan enrolled 156 patients in the Phase 2b trial of ataciguat in aortic stenosis; baseline data cover the first 139 intent-to-treat participants.

  • Primary Endpoint Moved to Week 48

    The aortic valve calcium endpoint will now be assessed at Week 48 alongside aortic valve area and cardiac structure/function measures. The amendment was made under blinded conditions and was not prompted by any safety finding.

  • Topline Data Pushed to 2H 2027

    Week 48 topline is now expected in the second half of 2027, with an internal Week 24 interim analysis and a Phase 3 development plan update in the first half of 2027.

  • Real-World Data Inform Phase 3 Design

    In roughly 45,000 people with mild-to-moderate AS, baseline aortic valve area was the strongest predictor of progression and about 27% progressed rapidly (AVA decline of at least 0.1 cm²/year); baseline AVC did not distinguish rapid from normal progressors.


Analysis · KARD · Life Sciences

Enrollment of 156 patients is the milestone the market was waiting for, but the more consequential news is the protocol amendment: the primary aortic valve calcium endpoint now reads out at Week 48 instead of an earlier point, and topline data slipped to the second half of 2027. Management says the change was made blinded and was not driven by any safety finding — the baseline AVC spread (320 to 1,983 Agatston units) simply means calcium accrues at each patient's own rate, so more time is needed to separate ataciguat from placebo. That pushes the key binary readout for the lead program roughly a year out and adds a Week 24 internal interim analysis plus a Phase 3 design update in the first half of 2027. The 45,000-patient real-world dataset is the constructive counterweight: it identifies rapid progressors and supports the patient-selection and endpoint design for the Phase 3 registrational trial.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 35.1% of the 2636 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, KARD was trading at $15.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $12.23 to $27.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

KARD - Latest Insights

KARD
Nov 06, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $15.52
Real-time Price: $15.70 info
Change: +$0.180 (+1%) info
Market Cap: $1.451B info
KARD
Aug 11, 2026, 7:10 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $20.41
Real-time Price: $15.70 info
Change: -$4.71 (-23%) info
Market Cap: $1.451B info
KARD
Aug 11, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $20.41
Real-time Price: $15.70 info
Change: -$4.71 (-23%) info
Market Cap: $1.451B info
KARD
Aug 11, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $20.41
Real-time Price: $15.70 info
Change: -$4.71 (-23%) info
Market Cap: $1.451B info
KARD
Jun 29, 2026, 4:05 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
Price at Filing: $25.90
Real-time Price: $15.70 info
Change: -$10.20 (-39%) info
Market Cap: $1.451B info